<DOC>
	<DOCNO>NCT01159210</DOCNO>
	<brief_summary>The purpose study assess efficacy safety Prothromplex Total treatment immediate reversal oral anticoagulant therapy vitamin K antagonists patient acquire deficiency prothrombin complex coagulation factor ( II , VII , IX , X ) . Upon enrolment , subject receive Prothromplex Total treatment acute bleed due oral anticoagulant prevention excessive bleeding interventional procedure ( Day 1 ) . Additional dos Prothromplex Total may administer discretion investigator . Efficacy safety assessment perform period 72 ( Â± 4 ) hour administration last dose Prothromplex Total discharge hospital , whichever occur first .</brief_summary>
	<brief_title>Efficacy Safety Prothromplex Total ( Prothrombin Complex Concentrate ) Oral Anticoagulant Reversal</brief_title>
	<detailed_description />
	<mesh_term>Anticoagulants</mesh_term>
	<mesh_term>Thrombin</mesh_term>
	<criteria>Subject least 16 year old enrolment acquire deficiency prothrombin complex coagulation factor ( II , VII , IX , X ) , due oral anticoagulation vitamin K antagonist ( e.g . coumarin , warfarin ) , require reversal oral anticoagulation urgent surgery , invasive procedure acute bleed episode Subject parent/legally authorise representative provide write informed consent Subject INR &gt; = 2,0 screen Subject willing able comply requirement protocol Subject laboratory and/or clinical symptom clearly indicative overt disseminate intravascular coagulation ( DIC ) Subject treat whole blood , fresh frozen plasma ( FFP ) , platelet within 6 hour prior study enrolment Subject hypersensitivity prothrombin complex concentrate ( PCC ) constituent ( include heparininduced thrombocytopenia ) Subject blood loss &gt; = 5 unit blood Subject hereditary thrombophilia bleed disorder Subject life expectancy &lt; 3 month Subject oral anticoagulant treatment period &lt; 4 week treatment thrombotic event deep vein thrombosis pulmonary embolism Subject acute ischemic cardiovascular disorder Subject suspect sepsis Subject acute chronic liver failure ( hepatic cirrhosis ChildPUGH score C ) Subject participate another clinical study involve investigational product ( IP ) investigational device within 30 day prior enrolment schedule participate another clinical study involve IP investigational device course study</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>